A5029428855- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Diverticular Disease and Complications
- Biosimilars and Bioanalytical Methods
- Gut microbiota and health
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Pharmaceutical studies and practices
- Mycobacterium research and diagnosis
- IL-33, ST2, and ILC Pathways
- Tuberculosis Research and Epidemiology
- Clostridium difficile and Clostridium perfringens research
- Pregnancy and Medication Impact
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Diagnosis and treatment of tuberculosis
- Colorectal Cancer Surgical Treatments
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Screening and Detection
KU Leuven
2016-2025
Universitair Ziekenhuis Leuven
2016-2025
Catholic University of America
2025
Università Cattolica del Sacro Cuore
2024
University of Cincinnati
2024
Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata
2023-2024
Montavid Thermodynamic Research Group
2022
Yale University
2018-2021
AbbVie (United States)
2021
Boehringer Ingelheim (India)
2021
<h3>Objective</h3> Bacteria play an important role in the onset and perpetuation of intestinal inflammation inflammatory bowel disease (IBD). Unlike Crohn9s (CD), which dysbiosis has been better characterised, ulcerative colitis (UC), only small cohorts have studied showed conflicting data. Therefore, we evaluated a large cohort if microbial signature described CD is also present UC, could characterise predominant UC. To assess functional impact dysbiosis, quantified bacterial metabolites....
Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become goal treatment IBD we examined how reliably levels reflect activity. In all, 126 patients and 32 irritable syndrome (IBS) needing colonoscopy delivered sample feces prior to the start cleansing. Besides collection symptom scores blood tests, experienced endoscopists recorded Simple Endoscopic Score for Crohn's Disease (SES-CD) Index Severity (CDEIS) (CD) Mayo endoscopic score...
Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on long-term outcome IFX CD is still debated.We studied during 214 patients. A total 183 (85.5%) responded to induction therapy and 31 (14.5%) were primary nonresponders. They underwent lower gastrointestinal (GI) endoscopy within a median 0.7 months (interquartile range [IQR] 0.1-6.8) prior first after 6.7 (IQR 1.4-24.6) start further analyzed. The relationship between was...
<h3>Background and aims:</h3> This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during median follow-up 55 months (interquartile range (IQR) 27–83). <h3>Methods:</h3> The primary analysis looked at proportion initial response to IFX who had sustained end follow-up. effects on course CD as reflected by rate surgery hospitalisations need for corticosteroids were also analysed....
<h3>Background and aims:</h3> This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated drug over a 14-year period. <h3>Methods:</h3> The medical records 734 IBD 666 control not were reviewed for adverse events. time onset outcome, severity concomitant medication recorded. <h3>Results:</h3> Patients controls followed up serious events median 58 months (IQR 33–88) 144 83–163), respectively. 112 severe occurred 93 (13%) 157 126 (19%) (OR...
<h3>Background and aims:</h3> Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to up 30% reaching remission. The mechanism resistance anti-tumour necrosis factor α (anti-TNFα) unknown. This study used colonic mucosal gene expression provide a predictive response signature infliximab in colitis. <h3>Methods:</h3> Two cohorts who received their first refractory were studied. Response was defined as endoscopic histological healing. Total RNA from...
<h3>Objective</h3> Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease often leading to end-stage disease. Its pathogenesis remains largely unknown, although frequent concomitant IBD hints towards common factors underlying gut and bile duct inflammation. Considering the mounting evidence on involvement of intestinal microbiota in initiating determining phenotype, we investigated composition patients with PSC. <h3>Design</h3> Stool samples were collected from 147...
Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical trials inflammatory bowel diseases. Accumulating evidence indicates that may change natural course of disease by decreasing need for surgery and reducing hospitalization rates both ulcerative colitis Crohn's disease. Mucosal also prevent development long-term complications, such damage colorectal cancer colitis. Histologic be ultimate colitis, whereas its impact on is unknown. Complete required before...
The endometrium, which is of crucial importance for reproduction, undergoes dynamic cyclic tissue remodeling. Knowledge its molecular and cellular regulation poor, primarily owing to a lack study models. Here, we have established novel promising organoid model from both mouse human endometrium. Dissociated endometrial tissue, embedded in Matrigel under WNT-activating conditions, swiftly formed structures that showed long-term expansion capacity, reproduced the histological phenotype tissue's...
Background and Aims: Faecal microbiota transplantation is a successful therapy for patients with refractory Clostridium difficile infections. It has also been suggested as treatment option inflammatory bowel disease, given the role of intestinal in this disease. We assessed impact faecal disease studied predictors clinical (non-)response microbial profiles donors patients.
OBJECTIVES: Endoscopic mucosal healing is a key endpoint for the treatment of ulcerative colitis (UC). The role microscopic activity in predicting disease relapse has not been fully assessed. We aimed to investigate predictive serologic and histologic markers on UC patients with endoscopically inactive disease. METHODS: Adult (Mayo 0) 12-month follow-up between 2008 2011 were retrospectively included. An expert pathologist evaluated all colonic biopsies (Geboes score) presence basal...
Stem cells generate rapidly dividing transit-amplifying that have lost the capacity for self-renewal but cycle a number of times until they exit cell and undergo terminal differentiation. We know very little type signals trigger earliest steps stem differentiation mediate to transition. show in normal intestinal epithelium, endoplasmic reticulum (ER) stress activity unfolded protein response (UPR) are induced at transition from cell. Induction ER causes loss stemness Perk-eIF2α-dependent...
Biosimilars of infliximab were first approved by the European Medicine Agency in 2013,1 , 2 based on pre-clinical studies biosimilarity and clinical data coming from two randomised controlled trials conducted rheumatoid arthritis [RA] ankylosing spondylitis [AS].3 4 Initially Crohn’s Colitis Organisation [ECCO] raised some caution use biosimilars.5 This cautious approach was also supported several national inflammatory bowel disease [IBD] societies5–12 [Table 1]. An insufficient...
Intestinal barrier defects are common in patients with inflammatory bowel disease (IBD). To identify which components could underlie these changes, we performed an in-depth analysis of epithelial genes IBD.A set 128 intestinal was selected. Polygenic risk scores were generated based on selected gene variants that associated Crohn's (CD) or ulcerative colitis (UC) our study. Gene expression analyzed using microarray and quantitative reverse transcription polymerase chain reaction. Influence...